Search

Your search keyword '"Kukreti, Vishal"' showing total 163 results
Start Over Author "Kukreti, Vishal" Search Limiters Academic (Peer-Reviewed) Journals
163 results on '"Kukreti, Vishal"'

15. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Author

Avet-Loiseau, Hervé, Fonseca, Rafael, Siegel, David, Dimopoulos, Meletios A., Špička, Ivan, Masszi, Tamás, Hájek, Roman, Rosiñol, Laura, Goranova-Marinova, Vesselina, Mihaylov, Georgi, Maisnar, Vladimír, Mateos, Maria-Victoria, Wang, Michael, Niesvizky, Ruben, Oriol, Albert, Jakubowiak, Andrzej, Minarik, Jiri, Palumbo, Antonio, Bensinger, William, Kukreti, Vishal, Ben-Yehuda, Dina, Stewart, A.Keith, Obreja, Mihaela, and Moreau, Philippe

Published
2016
Full Text
View/download PDF

16. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Author

Assouline, Sarit E., Nielsen, Torsten Holm, Yu, Stephen, Alcaide, Miguel, Chong, Lauren, MacDonald, David, Tosikyan, Axel, Kukreti, Vishal, Kezouh, Abbas, Petrogiannis-Haliotis, Tina, Albuquerque, Marco, Fornika, Daniel, Alamouti, Sepideh, Froment, Remi, Greenwood, Celia M.T., Oros, Kathleen Klein, Camglioglu, Errol, Sharma, Ayushi, Christodoulopoulos, Rosa, Rousseau, Caroline, Johnson, Nathalie, Crump, Michael, Morin, Ryan D., and Mann, Koren K.

Published
2016
Full Text
View/download PDF

19. Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer

Author

Krzyzanowska, Monika K., MacKay, Cassandra, Han, Heekyung, Eberg, Maria, Gandhi, Sonal, Laferriere, Nicole B., Powis, Melanie, Howell, Doris, Atzema, Clare L., Chan, Kelvin K. W., Kukreti, Vishal, Mitchell, Sandra, Nayer, Marla, Pasetka, Mark, Knittel-Keren, Dafna, and Redwood, Erin

Published
2019
Full Text
View/download PDF

20. Five hematologic tests and treatments to question

Author

Hicks, Lisa K., Bering, Harriet, Carson, Kenneth R., Haynes, Adam E., Kleinerman, Judith, Kukreti, Vishal, Ma, Alice, Mueller, Brigitta U., O’Brien, Sarah H., Panepinto, Julie A., Pasquini, Marcelo C., Rajasekhar, Anita, Sarode, Ravi, and Wood, William A.

Published
2014
Full Text
View/download PDF

25. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Author

Siegel, David S., Martin, Thomas, Wang, Michael, Vij, Ravi, Jakubowiak, Andrzej J., Lonial, Sagar, Trudel, Suzanne, Kukreti, Vishal, Bahlis, Nizar, Alsina, Melissa, Chanan-Khan, Asher, Buadi, Francis, Reu, Frederic J., Somlo, George, Zonder, Jeffrey, Song, Kevin, Stewart, A. Keith, Stadtmauer, Edward, Kunkel, Lori, Wear, Sandra, Wong, Alvin F., Orlowski, Robert Z., and Jagannath, Sundar

Published
2012
Full Text
View/download PDF

26. Impact of a Training Program on Oncology Nurses' Confidence in the Provision of Self-Management Support and 5As Behavioral Counseling Skills.

Author

Howell, Doris, McGowan, Patrick, Bryant-Lukosius, Denise, Kirkby, Ryan, Powis, Melanie, Sherifali, Diana, Kukreti, Vishal, Rask, Sara, and Krzyzanowska, Monica K.

Subjects
NURSING education, ONCOLOGY nursing, NATIONAL competency-based educational tests, SOCIAL support, COUNSELING, CONFIDENCE, SELF-management (Psychology), CANCER patients, ABILITY, TRAINING, RANDOMIZED controlled trials, HEALTH behavior, CLINICAL competence, RESEARCH funding, EDUCATIONAL outcomes, NURSING assessment
Abstract

Simple Summary: Cancer patients and their families require support to effectively self-manage the medical, emotional, and lifestyle consequences of cancer. In this paper, we describe a training program that showed improvement in oncology nurses confidence in the microskills required for the provision of self-management support to patients for application in routine care and in roles as cancer coaches before and after training at three cancer centres in Ontario, Canada. Self-management support is lacking in cancer care and little attention has been focused on the required preparation of nurses to provide self-management support and behavior change counseling. Our training program may have potential for improving nurses' provision of self-management support, however, further testing in a larger population of nurses is required to assess effects on nurses skills and its impact on patient uptake of self-management behaviors and health outcomes. Background: Cancer patients and their families play a central role in the self-management of the medical, emotional, and lifestyle consequences of cancer. Nurses with training in self-management support can enable cancer patients to better manage the effects of cancer and treatment. Methods: As part of a randomized controlled trial, we developed a training program to build nurses' confidence in the provision of self-management support (SMS). The SMS skills taught were adapted from the Stanford Peer Support training programs and embedded within the 5As (Assess, Advise, Agree, Assist, and Arrange) behavioral counseling process. We evaluated the impact of the training program on oncology nurses' and coaches' confidence using a Student's t-test for paired samples in a nonrandomized, one-group pre/postsurvey. Results: Participants were experienced oncology nurses from three participating cancer centers. A two-tailed Student's t-test for paired samples showed a significant improvement in nurses' confidence for the 15 SMS microskills targeted in the training between the pretest and post-test as follows: for Center 1, a mean difference of 0.79 (t = 7.18, p ≤ 0.00001); for Center 2, a mean difference of 0.73 (t = 8.4, p ≤ 0.00001); for Center 3, a mean difference of 1.57 (t = 11.45, p ≤ 0.00001); and for coaches, a mean difference of 0.52 (t = 7.6, p ≤ 0.00001). Conclusions: Our training program improved oncology staff nurses' and cancer coaches' confidence in 15 SMS microskills and has potential for SMS training of nurses in routine care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Author

Vij, Ravi, Wang, Michael, Kaufman, Jonathan L., Lonial, Sagar, Jakubowiak, Andrzej J., Stewart, A. Keith, Kukreti, Vishal, Jagannath, Sundar, McDonagh, Kevin T., Alsina, Melissa, Bahlis, Nizar J., Reu, Frederic J., Gabrail, Nashat Y., Belch, Andrew, Matous, Jeffrey V., Lee, Peter, Rosen, Peter, Sebag, Michael, Vesole, David H., Kunkel, Lori A., Wear, Sandra M., Wong, Alvin F., Orlowski, Robert Z., and Siegel, David S.

Published
2012
Full Text
View/download PDF

29. Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma.

Author

Manji, Farheen, Bhella, Sita, Kridel, Robert, Kukreti, Vishal, Kuruvilla, John, Prica, Anca, and Crump, Michael

Subjects
FOLLICULAR lymphoma, COMPUTED tomography, CANCER treatment, ASYMPTOMATIC patients, DIFFUSE large B-cell lymphomas
Abstract

Interim imaging with computed tomography (iCT) to assess response is common during frontline chemoimmunotherapy for follicular lymphoma (FL), but there is little evidence of its utility. We retrospectively reviewed outcomes of iCT in 190 patients with biopsy-proven FL who received first-line chemoimmunotherapy from 2003–2018. Most iCTs showed partial response (PR, 83%), with a minority showing complete response (CR, 8%) or stable disease (5%). Seven patients (4%) had radiographic disease progression (PD) on iCT; on repeat biopsy, four had another malignancy identified and three had transformation to DLBCL. Only one had asymptomatic PD. The 3-year PFS of all patients was 74% (median follow up 75 months). Patients with PR on iCT had similar 3-year PFS and OS as those with CR. In conclusion, iCT has limited utility in identifying patients with asymptomatic early progression during first-line treatment. Patients with PD mid-treatment warrant biopsy to identify histologic transformation or other malignancies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Author

Stewart, Keith A., Rajkumar, Vincent S., Dimopoulos, Meletios A., Masszi, Tamás, Špička, Ivan, Oriol, Albert, Hájek, Roman, Rosiñol, Laura, Siegel, David S., Mihaylov, Georgi G., Goranova-Marinova, Vesselina, Rajnics, Péter, Suvorov, Aleksandr, Niesvizky, Ruben, Jakubowiak, Andrzej J., San-Miguel, Jesus F., Ludwig, Heinz, Wang, Michael, Maisnar, Vladimír, Minarik, Jiri, Bensinger, William I., Mateos, Maria-Victoria, Ben-Yehuda, Dina, Kukreti, Vishal, Zojwalla, Naseem, Tonda, Margaret E., Yang, Xinqun, Xing, Biao, Moreau, Philippe, and Palumbo, Antonio

Published
2015
Full Text
View/download PDF

43. From T-antigen to plasmalogen-derived aldehydes: the identification of a marker of colorectal cancer in human rectal mucous

Author

Krepinsky, Jiri J., Kandel, Gabor P., Yeung, Ka Sing, Chociej, Jacek, Chen, Min, Cohen, Gideon, Douglas, Stephen P., Furrer, Rudolf, Kukreti, Vishal, Lupescu, Niculina, Richens, Enoka, and Tanner, Keith L.

Subjects
Colorectal cancer -- Causes of, Oxidation-reduction reaction -- Analysis, Chemical tests and reagents, Schiff bases, Carbohydrates, Galactose, Antigens, Aldehydes, Chemical research -- Analysis
Abstract

Recently, a simple noninvasive screening test for colorectal cancer was proposed, based on a hypothesis involving galactose-containing carbohydrate moieties such as the Thomsen-Friedenreich antigen. According to the hypothesis, such carbohydrate moieties, present in the human rectal mucous of patients with colorectal cancer, can be specifically oxidized with galactose oxidase to form substances that, upon reaction with Schiff reagent, yield purple (magenta) coloured compounds. While evaluating this proposed test, we discovered that the colour formation is not due to the proposed reaction between oxidized galactose moieties present in rectal mucous and Schiff reagent. We found instead that the mucous from colorectal cancer patients contains compounds that form purple (magenta) adducts with the Schiff reagent directly, i.e., they do not require oxidation by galactose oxidase. We have identified these compounds as long-chain aliphatic aldehydes, mainly palmitic aldehydes [C.sub.15][H.sub.31]CH=O and stearic aldehyde [C.sub.17][H.sub.35]CH=O. We have further found that the aldehydes originate from plasmalogens present in the phospholipid fraction of the mucous obtained from colorectal cancer patients. The aldehydes, present in plasmalogens as enol ethers, are released by the acidity of the Schiff reagent and in turn react with the Schiff reagent to form the coloured adducts. Correct identification of these markers could lead to the development of a more accurate colorectal cancer screening tool and to a deeper understanding of colorectal carcinogenesis. Key words: T-antigen, plasmalogen-derived aldehydes, colorectal cancer marker.

Published
2003

44. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.

Author

Rivera Duarte, Alfonso, Reece, Donna, Li, Xuan, Xu, Wei, Paul, Harminder, Masih-Khan, Esther, Winter, Andrew, Tiedemann, Rodger, Prica, Anca, Chen, Christine, Trudel, Suzanne, and Kukreti, Vishal

Subjects
AMYLOIDOSIS, TREATMENT duration, PROGRESSION-free survival, MULTIPLE myeloma
Abstract

The main objective of treatment in systemic light chain amyloidosis (AL amyloidosis) is to achieve the best hematological response. Deeper responses are associated with better organ responses and survival. In this study, we analysed the efficacy of prolonged duration treatment after first line in patients with AL amyloidosis. Retrospective analysis that included patients older than 18 years with AL amyloidosis. We excluded patients with more than 30% marrow plasmacytosis or concurrent multiple myeloma. Two cohorts identified accordingly if they received or not prolonged treatment after the first line. Survival analysis regarding progression free survival (PFS) and overall survival (OS) estimated with Kaplan–Meier and comparisons between groups with log-rank. Thirty-eight patients were included in the analysis with a median age of 55 years. Twenty-one patients received prolonged duration treatment and 17 did not. In the prolonged duration group, after a median duration of 12 months, the median PFS was 58.8 months. In the fixed duration treatment group, PFS was 30.6 months. The difference was significant with p =.0045 favouring prolonged duration treatment. Organ response was sustained for a longer period in the prolonged duration treatment group. For OS, the difference was not significant. Prolonged duration treatment in patients with systemic light chain amyloidosis correlated with better PFS and deeper organ responses. Prospective studies are needed to analyse this further. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.

Author

Lebel, Eyal, Li, Xuan, Paul, Harminder, Masih‐Khan, Esther, Bhella, Sita, Chen, Christine, Prica, Anca, Reece, Donna, Tiedemann, Rodger, Trudel, Suzanne, and Kukreti, Vishal

Subjects
MULTIPLE myeloma, AUTOGRAFTS, PROGNOSIS, LENALIDOMIDE, MELPHALAN
Abstract

Objectives: The prognostic value of kinetics of response to multiple myeloma (MM) therapy is controversial. We aimed to expand the knowledge on this topic by reviewing the kinetics of response to both first‐ and second‐line MM therapy, utilizing a homogeneously treated cohort and analyzing separately both M‐spike and light chain (LC) responses for each patient. Methods: We reviewed all patients who received first‐line cyclophosphamide, bortezomib and dexamethasone induction followed by autologous transplant with melphalan and lenalidomide maintenance in our center between 2007 and 2019. Results: Analyzing 360 patients, we observed no correlation between response kinetics to first‐ versus second‐line therapy at the individual patient level. Time to best response to first‐line therapy was not a predictor of outcome; however, longer time to best response was highly predictive of a favorable outcome in the second‐line setting, independent of other factors. Patients with IgA‐MM cleared their M‐spike faster than IgG‐MM, probably reflecting different half‐lives of these isotypes rather than disease biology, as the clearance of LC in both subtypes was similar. Conclusions: Analyzing both M‐spike and LC responses in a homogenously treated cohort, we identified important insights regarding the prognostic value of kinetic patterns. Prospective analysis may shed more light on unsolved questions. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

Author

Zangari, Maurizio, Aujay, Monette, Zhan, Fenghuang, Hetherington, Kristina L., Berno, Tamara, Vij, Ravi, Jagannath, Sundar, Siegel, David, Keith Stewart, A., Wang, Luhua, Orlowski, Robert Z., Belch, Andrew, Jakubowiak, Andrzej, Somlo, George, Trudel, Suzanne, Bahlis, Nizar, Lonial, Sagar, Singhal, Seema, Kukreti, Vishal, and Tricot, Guido

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results